tiprankstipranks
Trending News
More News >

Neuren Pharmaceuticals Updates on Share Buy-Back Program

Story Highlights
Neuren Pharmaceuticals Updates on Share Buy-Back Program

Don’t Miss TipRanks’ Half-Year Sale

Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.

Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program. As of the latest notification, the company has repurchased a total of 3,871,192 securities, with an additional 36,568 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and enhance shareholder value.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological conditions. The company is known for its work in creating treatments aimed at improving the quality of life for patients with neurodevelopmental and neurodegenerative disorders.

YTD Price Performance: 10.08%

Average Trading Volume: 723,364

Technical Sentiment Signal: Buy

Current Market Cap: A$1.74B

For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1